| Inhibition of intestinal OATP2B1 by the calcium receptor antagonist ronacaleret results in a significant drug-drug interaction by causing a 2-fold decrease in exposure of … M Johnson, D Patel, C Matheny, M Ho, L Chen, H Ellens Drug Metabolism and Disposition 45 (1), 27-34, 2017 | 43 | 2017 |
| The evolving druggability and developability space: chemically modified new modalities and emerging small molecules W Yang, P Gadgil, VR Krishnamurthy, M Landis, P Mallick, D Patel, ... The AAPS Journal 22, 1-14, 2020 | 40 | 2020 |
| Development and in-vivo evaluation of ondansetron gels for transdermal delivery DR Patel, A Joshi, HH Patel, G Stagni Drug development and industrial pharmacy 41 (6), 1030-1036, 2015 | 24 | 2015 |
| Synthesis, Structure–Activity Relationships, and In Vivo Evaluation of Novel Tetrahydropyran-Based Thiodisaccharide Mimics as Galectin-3 Inhibitors Journal of Medicinal Chemistry, 2021 | 18 | 2021 |
| Identification of monosaccharide derivatives as potent, selective, and orally bioavailable inhibitors of human and mouse galectin-3 C Liu, PR Jalagam, J Feng, W Wang, T Raja, MR Sura, RK Manepalli, ... Journal of Medicinal Chemistry 65 (16), 11084-11099, 2022 | 15 | 2022 |
| Modulating target engagement of small molecules via drug delivery: approaches and applications in drug discovery and development W Yang, SN Bhattachar, PJ Patel, M Landis, D Patel, DL Reid, MD Romic Drug discovery today 26 (3), 713-723, 2021 | 4 | 2021 |
| Single-species allometric scaling: a strategic approach to support drug discovery D Patel, E Dierks Journal of Pharmaceutical Research International 22 (3), 2018 | 4 | 2018 |
| Application and impact of human dose projection from discovery to early drug development D Patel, W Yang, M Lipert, T Wu AAPS PharmSciTech 21, 1-9, 2020 | 1 | 2020 |
| Development and In-Vivo Evaluation of Ondansetron Gels for Transdermal Drug Delivery DR Patel Long Island University, The Brooklyn Center, 2014 | | 2014 |
Liangfu ChenDirector, Preclinical Development, GlaxoSmithKlineVerified email at gsk.com
Liangfu ChenDirector, Preclinical Development, GlaxoSmithKlineVerified email at gsk.com